151 related articles for article (PubMed ID: 38331457)
1. Somatostatin Receptor Imaging with [
Dubash S; Barwick TD; Kozlowski K; Rockall AG; Khan S; Khan S; Yusuf S; Lamarca A; Valle JW; Hubner RA; McNamara MG; Frilling A; Tan T; Wernig F; Todd J; Meeran K; Pratap B; Azeem S; Huiban M; Keat N; Lozano-Kuehne JP; Aboagye EO; Sharma R
J Nucl Med; 2024 Feb; 65(3):416-22. PubMed ID: 38331457
[TBL] [Abstract][Full Text] [Related]
2. Targeting somatostatin receptors: preclinical evaluation of novel 18F-fluoroethyltriazole-Tyr3-octreotate analogs for PET.
Leyton J; Iddon L; Perumal M; Indrevoll B; Glaser M; Robins E; George AJ; Cuthbertson A; Luthra SK; Aboagye EO
J Nucl Med; 2011 Sep; 52(9):1441-8. PubMed ID: 21852355
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution and first clinical results of
Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
[TBL] [Abstract][Full Text] [Related]
4. Clinical Translation of a Click-Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors.
Dubash SR; Keat N; Mapelli P; Twyman F; Carroll L; Kozlowski K; Al-Nahhas A; Saleem A; Huiban M; Janisch R; Frilling A; Sharma R; Aboagye EO
J Nucl Med; 2016 Aug; 57(8):1207-13. PubMed ID: 27173162
[TBL] [Abstract][Full Text] [Related]
5.
Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Boeckxstaens L; Dekervel J; Vandamme T; Lybaert W; den Broeck BV; Laenen A; Clement PM; Geboes K; Cutsem EV; Stroobants S; Verslype C; Bormans G; Deroose CM
J Nucl Med; 2023 Apr; 64(4):632-638. PubMed ID: 36265911
[No Abstract] [Full Text] [Related]
6. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
Meisetschläger G; Poethko T; Stahl A; Wolf I; Scheidhauer K; Schottelius M; Herz M; Wester HJ; Schwaiger M
J Nucl Med; 2006 Apr; 47(4):566-73. PubMed ID: 16595488
[TBL] [Abstract][Full Text] [Related]
7. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of
Zhu W; Cheng Y; Jia R; Zhao H; Bai C; Xu J; Yao S; Huo L
J Nucl Med; 2021 Oct; 62(10):1398-1405. PubMed ID: 33579804
[No Abstract] [Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9.
Leupe H; Ahenkorah S; Dekervel J; Unterrainer M; Van Cutsem E; Verslype C; Cleeren F; Deroose CM
J Nucl Med; 2023 Jun; 64(6):835-841. PubMed ID: 37169533
[TBL] [Abstract][Full Text] [Related]
10. [
Allott L; Dubash S; Aboagye EO
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32252406
[TBL] [Abstract][Full Text] [Related]
11. [
Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Dekervel J; Van Cutsem E; Verslype C; Van Laere K; Bormans G; Deroose CM
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3033-3046. PubMed ID: 32617641
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
13. Head-to-Head Comparison of
Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
[No Abstract] [Full Text] [Related]
14. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
15. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
16. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution, pharmacokinetics, dosimetry of [
Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Tripathi M; ArunRaj ST; Sarswat S; Bal C
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1915-1931. PubMed ID: 33244617
[TBL] [Abstract][Full Text] [Related]
18. Prospective comparison of [
Boeckxstaens L; Pauwels E; Vandecaveye V; Deckers W; Cleeren F; Dekervel J; Vandamme T; Serdons K; Koole M; Bormans G; Laenen A; Clement PM; Geboes K; Van Cutsem E; Nackaerts K; Stroobants S; Verslype C; Van Laere K; Deroose CM
EJNMMI Res; 2023 Jun; 13(1):53. PubMed ID: 37261615
[TBL] [Abstract][Full Text] [Related]
19. The potential utility of [
Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
